Lannum joins Zimmer Biomet with more than 15 years of investor relations (IR) experience in the healthcare industry. Most recently, he served as senior vice president of Investor Strategy and Investor Relations Officer for Mallinckrodt Pharmaceuticals, where he consulted with executive management and the Board of Directors regarding the company's acquisitions, strategic direction and shareholder value optimization.
Prior to joining Mallinckrodt in 2015, Lannum led IR at Covidien plc and Tyco Healthcare for nine years. As vice president and Investor Relations Officer, he designed Covidien's IR program, oversaw the largest-ever healthcare initial public offering and led the IR effort through the company's merger with Medtronic Inc. in 2015.
Lannum's leadership at Covidien and Mallinckrodt has been recognized with numerous best-in-class honors, including an unprecedented five consecutive awards by IR Magazine for both Best U.S. Investor Relations Officer - Large Cap and Grand Prix - Best Overall Investor Relations from 2011 through 2015.
Founded in 1927 and headquartered in Warsaw, Ind., Zimmer Biomet designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products. The company's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Zimmer Biomet has operations in more than 25 countries around the world and sells products in more than 100 countries.